Replies to post #151449 on Biotech Values

[jq1234]

I don't know. I don't get a sense what he said was real what was just talk. He talks 797 a lot which I don't like that much. We'll see data from 520 and 614 at ASH. I am in wait and see mode. Have no expectation one way or the other.

[mcbio]

Why do you think Squarer is hyping this drug so much? He generally lists it in front of 614 when speaking of the proprietary pipeline.

Disagree on this. While 520 came first in the 1Q13 results PR, 614 has always come before 520 in actual presentations and quarterly CCs. Squarer seems to have much more hope for 614. I'll listen to today's CC and see if anything has changed.